Fulcrum Therapeutics, a clinical-stage biotechnology company focused on genetically defined rare diseases, reported a major operational shift in mid-2026 following safety-related discontinuation of its lead candidate pociredir. The company enacted an 85% workforce reduction to preserve capital and initiated a strategic review process to explore potential transactions. Despite substantial ongoing operating losses and an absence of approved products, Fulcrum maintains significant liquidity as it seeks to recalibrate its pipeline and long-term strategy. This transition underscores typical biotech sector risks tied to clinical trial outcomes, regulatory hurdles, and capital intensity prior to commercialization.